Abstract
Only one in every five children with autism is diagnosed before the age of 3 years. As a result, tens of thousands of children every year in the United States miss benefiting from early interventions and supports that could potentially optimize their lifetime outcomes. A major obstacle is the extremely limited access to high quality diagnosis. To address this challenge, biomarker-based objective procedures for early diagnosis and assessment of autism have already been clinically validated and cleared for broad implementation by the U.S. Food and Drug Administration. Broad community uptake of these science-based solutions, however, will require change in entrenched models of diagnostic care, and aggressive prioritization of the needs of the community at large.